Ixazomib is a glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. Among its listed roles, it functions as a apoptosis inducer, an orphan drug, a proteasome inhibitor, a drug metabolite and an antineoplastic agent. It belongs to the class of benzamides, a dichlorobenzene, a glycine derivative and a member of boronic acids. It is grouped under the following drug class(es): Proteasome inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include CHEBI:90942, DTXSID701025662 and MFCD18251438. Its PubChem CID is 25183872.
Ixazomib
| CAS No | 1072833-77-2 |
|---|---|
| Molecular Formula | C14H19BCl2N2O4 |
| Molecular Weight | 361.0 g/mol |
| Synonyms | [(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Ixazomib is a glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid.
The listed CAS number is 1072833-77-2.
The listed molecular formula is C14H19BCl2N2O4.
The listed molecular weight is 361.0 g/mol.
[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid.
The source lists CHEBI:90942, DTXSID701025662 and MFCD18251438.